Biomedical Prevensions

杜克大学艾滋病研究中心 (CFAR) 的主要任务是建立全面的艾滋病研究中心 对学术研究环境的基础设施支持，将有效促进合作和 杜克大学和整个国家 CFAR 的艾滋病毒/艾滋病调查员群体之间的协调 网络，从而提高其重大贡献的质量和数量以及对 领域。在这个具有竞争力的续订申请中，杜克 CFAR 建立在我们的成就之上 上一个融资周期，并扩大整体基础设施和方案支持，以继续提供 具有成本效益的最先进服务，并促进杜克大学的艾滋病毒/艾滋病合作研究计划。一个 我们非常成功的小额赠款机制主要针对早期阶段，奠定了坚实的基础 调查人员和我们同样成功的教师招聘工作。通过有效的战略规划 在此过程中，CFAR 领导层确定了七个具体目标来指导 CFAR 的成长和演变 未来5年。它们是：1）提供行政和科学领导并继续建设 并建立战略伙伴关系，2) 为创新的艾滋病毒/艾滋病研究提供指导和支持 通过一整套全面的机制，包括小额赠款、教师招聘和科学 工作组活动，3) 通过新的核心提供获得高度先进技术和培训的机会 服务，4) 提供高度创新和主动的生物统计和计算支持，5) 提供 随时获取患者标本并扩大社区外展，6) 支持跨学科研究 艾滋病毒相关结果的社会和行为决定因素，以及 7) 支持 NIH 举措并促进 CFAR 之间的合作。 CFAR 将加大力度吸引代表性不足的少数群体感染艾滋病毒/艾滋病 通过与杜克大学生物医学研究生多样性办公室建立新的合作伙伴关系进行研究。我们也将寻求 通过扩大小额赠款目标 RFA/共同资助，进一步参与我们的战略合作伙伴网络 模型是在 CFAR 和医学部之间的上一个资助周期中启动的。此次扩建， 以及对新建立的 CFAR 数据库和生物样本库以及 CFAR 活动的持续支持， 杜克大学医学院显着增加的机构支持将得到加强 外科。通过我们的战略规划流程，我们确定了五个优先领域 代表杜克大学创新研究的机会：1) 艾滋病相关恶性肿瘤和合并感染，2) HIV 与衰老，3) 潜伏期和根除，4) 心理健康、药物滥用和 HIV 结果，5) HIV 疫苗设计和评估。 CFAR 因发展和进一步探索的潜力而充满活力 这些机会是通过杜克大学和整个 CFAR 网络更密切的合作互动获得的。

The principal mission of the Duke Center for AIDS Research (CFAR) is to establish comprehensive infrastructure support to an academic research environment that will effectively promote collaboration and coordination among the community of HIV/AIDS investigators at Duke and throughout the national CFAR network, thereby enhancing both the quality and quantity of their significant contributions and overall impact to the field. In this competitive renewal application, the Duke CFAR builds upon our accomplishments of the previous funding cycle and expands the overall infrastructure and programmatic support to continue to provide cost effective state-of-the-art services and catalyzing collaborative HIV/AIDS research initiatives at Duke. A solid basis is formed by both our highly successful Small Grant mechanism aimed primarily at early stage investigators and our equally successful faculty recruitment efforts. Through an effective Strategic Planning Process, the CFAR leadership has identified seven Specific Aims to guide the CFAR’s growth and evolution over the next 5 years. These are: 1) to provide administrative and scientific leadership and continue to build and engage Strategic Partnerships, 2) to provide mentoring and support for innovative HIV/AIDS research through a comprehensive set of mechanisms, including Small Grants, faculty recruitments, and Scientific Working Group activities, 3) to provide access to highly advanced technologies and training through new Core services, 4) to provide highly innovative and proactive biostatistics and computational support, 5) to provide ready access to patient specimens and expanded community outreach, 6) to support interdisciplinary research on social and behavioral determinants of HIV-related outcomes, and 7) to support NIH initiatives and promote inter-CFAR collaborations. The CFAR will expand its efforts to attract underrepresented minorities to HIV/AIDS research through a new partnership with the Duke Office of Biomedical Graduate Diversity. We also will seek to further engage our network of Strategic Partnerships by expanding the Small Grant targeted RFA/co-funding model initiated in the previous funding cycle between the CFAR and Department of Medicine. This expansion, as well as continued support for the newly established CFAR Database and Biorepository and CFAR events, will be enhanced by a significant increase in Institutional Support from Duke’s School of Medicine and Department of Surgery. Through our Strategic Planning process, we have identified five priority areas that represent opportunities for innovative research at Duke: 1) AIDS-related Malignancies and Co-Infections, 2) HIV and Aging, 3) Latency and Eradication, 4) Mental Health, Substance Abuse, and HIV Outcomes and 5) HIV Vaccine Design and Evaluation. The CFAR is invigorated by the potential to develop and further explore these opportunities through closer collaborative interactions at Duke and across the CFAR network.